experimental melanoma

Summary

Summary: Experimentally induced tumor that produces MELANIN in animals to provide a model for studying human MELANOMA.

Top Publications

  1. pmc CTLA4 blockade and GM-CSF combination immunotherapy alters the intratumor balance of effector and regulatory T cells
    Sergio A Quezada
    Howard Hughes Medical Institute, Department of Immunology, Memorial Sloan Kettering Cancer Center, New York, New York, USA
    J Clin Invest 116:1935-45. 2006
  2. pmc CD8+ T cell immunity against a tumor/self-antigen is augmented by CD4+ T helper cells and hindered by naturally occurring T regulatory cells
    Paul A Antony
    Division of Surgery, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    J Immunol 174:2591-601. 2005
  3. ncbi Ink4a/arf deficiency promotes ultraviolet radiation-induced melanomagenesis
    Juan A Recio
    Laboratory of Molecular Biology, National Cancer Institute, Bethesda, Maryland 20892 4264, USA
    Cancer Res 62:6724-30. 2002
  4. pmc Tumor regression and autoimmunity after reversal of a functionally tolerant state of self-reactive CD8+ T cells
    Willem W Overwijk
    National Cancer Institute NCI, National Institute of Health, Bethesda, MD 20892 1502, USA
    J Exp Med 198:569-80. 2003
  5. ncbi Expression of CC chemokine receptor-7 and regional lymph node metastasis of B16 murine melanoma
    H E Wiley
    Dermatology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    J Natl Cancer Inst 93:1638-43. 2001
  6. ncbi Murine endothelial cell lines as models of tumor endothelial cells
    Jennifer Walter-Yohrling
    Genzyme Corporation, Framingham, Massachusetts 01701, USA
    Clin Cancer Res 10:2179-89. 2004
  7. ncbi Oncolytic immunovirotherapy for melanoma using vesicular stomatitis virus
    Rosa Maria Diaz
    Molecular Medicine Program, Mayo Clinic, Rochester, Minnesota 55905, USA
    Cancer Res 67:2840-8. 2007
  8. pmc Clinically proven markers of metastasis predict metastatic spread of human melanoma cells engrafted in scid mice
    A Thies
    Zentrum für Experimentelle Medizin, Institut für Anatomie II Experimentelle Morphologie, Universitatsklinikum Hamburg Eppendorf, Martinistrasse 52, Hamburg D 20246, Germany
    Br J Cancer 96:609-16. 2007
  9. pmc Concomitant tumor immunity to a poorly immunogenic melanoma is prevented by regulatory T cells
    Mary Jo Turk
    The Swim Across America Laboratory of Tumor Immunology, Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY 10021, USA
    J Exp Med 200:771-82. 2004
  10. ncbi Temporal targeting of tumour cells and neovasculature with a nanoscale delivery system
    Shiladitya Sengupta
    Biological Engineering Division, Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, USA
    Nature 436:568-72. 2005

Research Grants

Detail Information

Publications245 found, 100 shown here

  1. pmc CTLA4 blockade and GM-CSF combination immunotherapy alters the intratumor balance of effector and regulatory T cells
    Sergio A Quezada
    Howard Hughes Medical Institute, Department of Immunology, Memorial Sloan Kettering Cancer Center, New York, New York, USA
    J Clin Invest 116:1935-45. 2006
    ....
  2. pmc CD8+ T cell immunity against a tumor/self-antigen is augmented by CD4+ T helper cells and hindered by naturally occurring T regulatory cells
    Paul A Antony
    Division of Surgery, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    J Immunol 174:2591-601. 2005
    ..These findings reveal that Th cells can help break tolerance to a persisting self-Ag and treat established tumors through an IL-2-dependent mechanism, but requires simultaneous absence of naturally occurring T(reg) cells to be effective...
  3. ncbi Ink4a/arf deficiency promotes ultraviolet radiation-induced melanomagenesis
    Juan A Recio
    Laboratory of Molecular Biology, National Cancer Institute, Bethesda, Maryland 20892 4264, USA
    Cancer Res 62:6724-30. 2002
    ....
  4. pmc Tumor regression and autoimmunity after reversal of a functionally tolerant state of self-reactive CD8+ T cells
    Willem W Overwijk
    National Cancer Institute NCI, National Institute of Health, Bethesda, MD 20892 1502, USA
    J Exp Med 198:569-80. 2003
    ....
  5. ncbi Expression of CC chemokine receptor-7 and regional lymph node metastasis of B16 murine melanoma
    H E Wiley
    Dermatology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    J Natl Cancer Inst 93:1638-43. 2001
    ..CONCLUSION: Expression of a single chemokine receptor gene, CCR7, increased B16 cell metastasis to draining lymph nodes, suggesting that cancer cells may co-opt normal mechanisms of lymph node homing during metastasis...
  6. ncbi Murine endothelial cell lines as models of tumor endothelial cells
    Jennifer Walter-Yohrling
    Genzyme Corporation, Framingham, Massachusetts 01701, USA
    Clin Cancer Res 10:2179-89. 2004
    ..These cells can be used in in vitro angiogenesis assays for evaluating the potential antiangiogenic properties and interspecies cross-reactivity of novel compounds...
  7. ncbi Oncolytic immunovirotherapy for melanoma using vesicular stomatitis virus
    Rosa Maria Diaz
    Molecular Medicine Program, Mayo Clinic, Rochester, Minnesota 55905, USA
    Cancer Res 67:2840-8. 2007
    ..Therefore, our results show that strategies which enhance immune activation against tumor-associated antigens can also be used to enhance the efficacy of virotherapy...
  8. pmc Clinically proven markers of metastasis predict metastatic spread of human melanoma cells engrafted in scid mice
    A Thies
    Zentrum für Experimentelle Medizin, Institut für Anatomie II Experimentelle Morphologie, Universitatsklinikum Hamburg Eppendorf, Martinistrasse 52, Hamburg D 20246, Germany
    Br J Cancer 96:609-16. 2007
    ....
  9. pmc Concomitant tumor immunity to a poorly immunogenic melanoma is prevented by regulatory T cells
    Mary Jo Turk
    The Swim Across America Laboratory of Tumor Immunology, Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY 10021, USA
    J Exp Med 200:771-82. 2004
    ..These results show that regulatory T cells are the major regulators of concomitant tumor immunity against this weakly immunogenic tumor...
  10. ncbi Temporal targeting of tumour cells and neovasculature with a nanoscale delivery system
    Shiladitya Sengupta
    Biological Engineering Division, Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, USA
    Nature 436:568-72. 2005
    ..The technology can be extended to additional agents, so as to target multiple signalling pathways or distinct tumour compartments, enabling the model of an 'integrative' approach in cancer therapy...
  11. pmc A second tyrosinase-related protein, TRP-2, is a melanogenic enzyme termed DOPAchrome tautomerase
    K Tsukamoto
    Laboratory of Cell Biology, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892
    EMBO J 11:519-26. 1992
    ..We now report that TRP-2 (tyrosinase related protein-2), which maps to and is mutated at the slaty locus in mice, encodes a protein with DOPAchrome tautomerase activity...
  12. ncbi Low-level monocyte chemoattractant protein-1 stimulation of monocytes leads to tumor formation in nontumorigenic melanoma cells
    M Nesbit
    The Wistar Institute, 3601 Spruce Street, Philadelphia, PA 19104, USA
    J Immunol 166:6483-90. 2001
    ..This correlates with the degree of monocytic cell infiltration, which results in increased tumor vascularization and TNF-alpha production...
  13. pmc Tumor-induced sentinel lymph node lymphangiogenesis and increased lymph flow precede melanoma metastasis
    Maria I Harrell
    Division of Basic Sciences, Fred Hutchinson Cancer Research Center, Department of Comparative Medicine, University of Washington, 1100 Fairview Ave N, MS C2 023, P O Box 19024, Seattle, WA 98109, USA
    Am J Pathol 170:774-86. 2007
    ..Lymph node lymphangiogenesis and increased lymph flow through tumor-draining lymph nodes may actively promote metastasis via the lymphatics...
  14. ncbi The Abl interactor proteins localize to sites of actin polymerization at the tips of lamellipodia and filopodia
    T Stradal
    Institute of Molecular Biology, Austrian Academy of Sciences, 5020, Salzburg, Austria
    Curr Biol 11:891-5. 2001
    ..Our findings are the first to suggest a direct involvement of members of the Abi protein family in the control of actin polymerization in protrusion events, and establish the Abi proteins as potential regulators of motility...
  15. ncbi Interleukin 12 gene therapy of MHC-negative murine melanoma metastases
    P Nanni
    Institute for Cancer Research, University of Bologna, Italy
    Cancer Res 58:1225-30. 1998
    ..In conclusion, tumor therapy based on IL-12 gene transduction was effective on a MHC-negative metastatic tumor, suggesting a possible application to MHC-defective human neoplasms...
  16. ncbi Expression of matrix metalloproteinases in the microenvironment of spontaneous and experimental melanoma metastases reflects the requirements for tumor formation
    Uta B Hofmann
    Department of Dermatology, Julius Maximilian s University, Wurzburg, Germany
    Cancer Res 63:8221-5. 2003
    ....
  17. ncbi The anti-tumor activity of IL-12: mechanisms of innate immunity that are model and dose dependent
    M J Smyth
    Cancer Immunology, Peter MacCallum Cancer Institute, St Andrews Place, East Melbourne, Victoria, Australia
    J Immunol 165:2665-70. 2000
    ..Overall, both NK and NKT cells can contribute to natural and IL-12-induced immunity against tumors, and the relative role of each population is tumor and therapy dependent...
  18. ncbi Hypoxia influences vasculogenic mimicry channel formation and tumor invasion-related protein expression in melanoma
    Baocun Sun
    Department of Pathology, Tianjin Cancer Hospital, Tianjin Medical University, Tianjin 300060, PR China
    Cancer Lett 249:188-97. 2007
    ..Hypoxia can enhance tumor cell invasion and metastasis. The cause and the molecular mechanism are still not clear...
  19. pmc Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti-CTLA-4 antibodies
    Karl S Peggs
    Howard Hughes Medical Institute, Department of Immunology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Exp Med 206:1717-25. 2009
    ....
  20. ncbi The dynamics of the T-cell antitumor response: chemokine-secreting dendritic cells can prime tumor-reactive T cells extranodally
    C J Kirk
    Department of Surgery, University of Michigan Medical Center, Ann Arbor, Michigan 48109-0666, USA
    Cancer Res 61:8794-802. 2001
    ..Similar results were obtained in lymphotoxin alpha-/- mice, which lacked peripheral lymph nodes. Our data demonstrate that effective T-cell priming can occur extranodally and result in measurable antitumor effects in vivo...
  21. pmc Loading of oncolytic vesicular stomatitis virus onto antigen-specific T cells enhances the efficacy of adoptive T-cell therapy of tumors
    J Qiao
    Molecular Medicine Program, Mayo Clinic College of Medicine, Rochester, MN 55902, USA
    Gene Ther 15:604-16. 2008
    ....
  22. ncbi MMP9 induction by vascular endothelial growth factor receptor-1 is involved in lung-specific metastasis
    Sachie Hiratsuka
    Department of Genetics, Institute of Medical Science, University of Tokyo, Minato ku, Tokyo 108 8639, Japan
    Cancer Cell 2:289-300. 2002
    ..Thus, a block of MMP9 induction via VEGFR-1 inhibition could be useful for the prevention of tumor metastasis in lung...
  23. ncbi A single heteroclitic epitope determines cancer immunity after xenogeneic DNA immunization against a tumor differentiation antigen
    Jason S Gold
    Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Immunol 170:5188-94. 2003
    ....
  24. ncbi Simultaneous blockade of VEGFR-1 and VEGFR-2 activation is necessary to efficiently inhibit experimental melanoma growth and metastasis formation
    Jens Gille
    Department of Dermatology, J W Goethe University, Frankfurt am Main, Germany
    Int J Cancer 120:1899-908. 2007
    ....
  25. pmc Active immunization against the vascular endothelial growth factor receptor flk1 inhibits tumor angiogenesis and metastasis
    Yiwen Li
    ImClone Systems Incorporated, New York, NY 10014, USA
    J Exp Med 195:1575-84. 2002
    ..Thus, an active immunization strategy that targets an angiogenesis-related antigen on endothelium can inhibit angiogenesis and may be a useful approach for treating angiogenesis-related diseases...
  26. ncbi Endothelial P-selectin as a target of heparin action in experimental melanoma lung metastasis
    Ralf J Ludwig
    Department of Dermatology, Klinikum der J W Goethe Universitat, Frankfurt am Main, Germany
    Cancer Res 64:2743-50. 2004
    ..cell rolling but also attenuates melanoma metastasis formation in vivo, further supporting the concept that endothelial P-selectin expression may represent an additional target of heparin action in experimental melanoma lung metastasis.
  27. pmc The central role of CD4(+) T cells in the antitumor immune response
    K Hung
    Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, Maryland 21205, USA
    J Exp Med 188:2357-68. 1998
    ..Cytokines produced by these CD4(+) T cells activate eosinophils as well as macrophages that produce both superoxide and nitric oxide. Both of these cell types then collaborate within the site of tumor challenge to cause its destruction...
  28. ncbi Comparative analysis of necrotic and apoptotic tumor cells as a source of antigen(s) in dendritic cell-based immunization
    Y Kotera
    Department of Surgery, University of Michigan Medical Center, 1150 West Medical Center Drive, Ann Arbor, MI 48109-0666, USA
    Cancer Res 61:8105-9. 2001
    ....
  29. pmc Microphthalmia gene product as a signal transducer in cAMP-induced differentiation of melanocytes
    C Bertolotto
    Institut National de la Sante et de la Recherche Medicale U385, Biologie et Physiopathologie de la Peau, Faculte de Medecine, Paris, France
    J Cell Biol 142:827-35. 1998
    ..These findings disclose the mechanism by which cAMP stimulates tyrosinase expression and melanogenesis and emphasize the critical role of microphthalmia as signal transducer in cAMP-induced melanogenesis and pigment cell differentiation...
  30. pmc Positive and negative elements regulate a melanocyte-specific promoter
    P Lowings
    Eukaryotic Transcription Laboratory, Marie Curie Research Institute, Oxted, Surrey, United Kingdom
    Mol Cell Biol 12:3653-62. 1992
    ..The possible mechanisms underlying melanocyte-specific gene expression are discussed...
  31. ncbi Experimental melanoma metastasis in lungs of mice with congenital coagulation disorders
    Lois W Brüggemann
    Center for Experimental and Molecular Medicine, Academic Medical Center, Amsterdam, The Netherlands
    J Cell Mol Med 12:2622-7. 2008
    ....
  32. pmc Synergism of cytotoxic T lymphocyte-associated antigen 4 blockade and depletion of CD25(+) regulatory T cells in antitumor therapy reveals alternative pathways for suppression of autoreactive cytotoxic T lymphocyte responses
    R P Sutmuller
    Department of Immunohematology and Blood Transfusion, Tumor Immunology Lab, E3-Q, Leiden University Medical Center, 2300 RC Leiden, The Netherlands
    J Exp Med 194:823-32. 2001
    ..Simultaneous intervention with both regulatory mechanisms is therefore a promising concept for the induction of therapeutic antitumor immunity...
  33. ncbi Regulation of the innate and adaptive immune responses by Stat-3 signaling in tumor cells
    Tianhong Wang
    Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, Maryland 21205, USA
    Nat Med 10:48-54. 2004
    ..We propose that tumor Stat-3 activity can mediate immune evasion by blocking both the production and sensing of inflammatory signals by multiple components of the immune system...
  34. ncbi Chemoimmunotherapy for melanoma with dacarbazine and 2,4-dinitrochlorobenzene: results from a murine tumour model
    C Wack
    Department of Toxicology, , Versbacher Strasse 9, , Germany
    Melanoma Res 11:247-53. 2001
    ..In conclusion, we have established a model system that seems to be appropriate for both the optimization of this therapeutic regimen and the characterization of effector mechanisms...
  35. ncbi IFN-gamma mediates CD4+ T-cell loss and impairs secondary antitumor responses after successful initial immunotherapy
    Vanessa Berner
    Department of Microbiology and Immunology, University of Nevada at Reno, Reno, Nevada 89557, USA
    Nat Med 13:354-60. 2007
    ..Thus, although immunotherapeutic regimens inducing strong IFN-gamma responses can lead to successful early antitumor efficacy, they may also impair the development of durable antitumor responses...
  36. ncbi Cloning of the human DOPAchrome tautomerase/tyrosinase-related protein 2 gene and identification of two regulatory regions required for its pigment cell-specific expression
    K Yokoyama
    Department of Applied Physiology and Molecular Biology, Tohoku University School of Medicine, Miyagi, Japan
    J Biol Chem 269:27080-7. 1994
    ..Both regulatory regions contain a CANNTG motif, a well known binding site for a large family of transcription factors possessing a basic helix-loop-helix structure...
  37. ncbi Proangiogenic role of tumor-activated hepatic stellate cells in experimental melanoma metastasis
    Elvira Olaso
    University of the Basque Country, School of Medicine and Dentistry, Bizkaia, Spain
    Hepatology 37:674-85. 2003
    ....
  38. ncbi Cancer stem cells sustaining the growth of mouse melanoma are not rare
    Yong Zhong
    Department of Immunology, Cancer Institute, Peking Union Medical College and Chinese Academy of Medical Sciences, 17 Pan Jia Yuan Nan Li, Chao Yang, Beijing, China
    Cancer Lett 292:17-23. 2010
    ..The result of this study does not seem to support the current view that cancer stem cells (CSCs) responsible for the sustainable growth of tumor are rare...
  39. pmc Plasmacytoid dendritic cells induce NK cell-dependent, tumor antigen-specific T cell cross-priming and tumor regression in mice
    Chengwen Liu
    Department of Melanoma Medical Oncology, Center for Cancer Immunology Research, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA
    J Clin Invest 118:1165-75. 2008
    ..Our data thus demonstrated that activated pDCs are capable of initiating effective and systemic antitumor immunity through the orchestration of an immune cascade involving the sequential activation of NK cells, cDCs, and CD8(+) T cells...
  40. ncbi Involvement of very late activation antigen 4 (VLA-4) and vascular cell adhesion molecule 1 (VCAM-1) in tumor necrosis factor alpha enhancement of experimental metastasis
    H Okahara
    First Department of Surgery, School of Medicine, Juntendo University, Tokyo, Japan
    Cancer Res 54:3233-6. 1994
    ..These results indicate that the interaction between VLA-4 on tumor cells and vascular cell adhesion molecule 1 on activated endothelial cells is critically involved in TNF-alpha enhancement of metastasis...
  41. ncbi Divergent roles for CD4+ T cells in the priming and effector/memory phases of adoptive immunotherapy
    H M Hu
    Laboratory of Molecular and Tumor Immunology, Robert W Franz Cancer Research Center, Earle A Chiles Research Institute, Providence Portland Medical Center, Portland, OR 97213, USA
    J Immunol 165:4246-53. 2000
    ....
  42. pmc IL-15 enhances the in vivo antitumor activity of tumor-reactive CD8+ T cells
    Christopher A Klebanoff
    Howard Hughes Medical Institute National Institutes of Health Research Scholars Program, Bethesda, MD 20814, USA
    Proc Natl Acad Sci U S A 101:1969-74. 2004
    ..These results provide several avenues for improving adoptive immunotherapy of cancer in patients...
  43. ncbi Targeting of lymphotoxin-alpha to the tumor elicits an efficient immune response associated with induction of peripheral lymphoid-like tissue
    D Schrama
    Department of Dermatology, Julius-Maximilians-University, D-97080, , Germany
    Immunity 14:111-21. 2001
    ..Consequently, naive T cells may have been recruited to as well as primed and expanded in the lymphoid-like tissue induced by the lymphotoxin-alpha fusion protein at the tumor site...
  44. ncbi Transfection of macrophage inflammatory protein 1 alpha into B16 F10 melanoma cells inhibits growth of pulmonary metastases but not subcutaneous tumors
    Hendrik W van Deventer
    Division of Hematology Oncology, Department of Medicine, University of North Carolina, Chapel Hill, NC 27599, USA
    J Immunol 169:1634-9. 2002
    ..Our findings suggest that MIP-1 alpha is effective in preventing the initiation of metastasis, but not at sustaining an effective antitumor response...
  45. ncbi Regulation of tyrosinase mRNA in mouse melanoma cells by alpha-melanocyte-stimulating hormone
    D Rungta
    Department of Biochemistry and Molecular Biology, University of Oklahoma, Health Science Center, Oklahoma City, USA
    J Invest Dermatol 107:689-93. 1996
    ....
  46. ncbi TNF plays an essential role in tumor regression after adoptive transfer of perforin/IFN-gamma double knockout effector T cells
    Christian H Poehlein
    Laboratory of Molecular and Tumor Immunology, Robert W Franz Cancer Research Center, Earle A Chiles Research Institute, Providence Portland Medical Center, 4805 NE Glisan Street, Portland, OR 97213, USA
    J Immunol 170:2004-13. 2003
    ..These insights could be used to monitor and potentially tune the immune response to cancer vaccines...
  47. pmc Angiostatic activity of obtustatin as alpha1beta1 integrin inhibitor in experimental melanoma growth
    MEGHAN C BROWN
    Department of Neuroscience, Center for Neurovirology and Cancer Biology, Temple University, School of Medicine, Philadelphia, PA, USA
    Int J Cancer 123:2195-203. 2008
    ..of collagen receptor, alpha1beta1 integrin expressed on the endothelial cells on the development of experimental melanoma and pathological angiogenesis...
  48. pmc Coupling and uncoupling of tumor immunity and autoimmunity
    W B Bowne
    Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    J Exp Med 190:1717-22. 1999
    ..e., antibody versus CD8(+) T cell. However, both pathways led to tumor immunity and identical phenotypic manifestations of autoimmunity...
  49. pmc Hematopoietic stem cells promote the expansion and function of adoptively transferred antitumor CD8 T cells
    Claudia Wrzesinski
    National Cancer Institute, NIH, Bethesda, Maryland 20892, USA
    J Clin Invest 117:492-501. 2007
    ..These findings indicate that CD8(+) T cell-mediated tumor responses can be efficiently driven by HSCs in the myeloablative setting and have substantial implications for the design of new antitumor immunotherapies...
  50. ncbi Fas ligand breaks tolerance to self-antigens and induces tumor immunity mediated by antibodies
    Anna Katharina Simon
    MRC Human Immunology Unit and Nuffield Department of Medicine, Institute of Molecular Medicine, OX3 9DS, Oxford, United Kingdom
    Cancer Cell 2:315-22. 2002
    ..We show that protected mice recognize melanocyte differentiation self-antigens. Importantly, tumor immunity is mediated by antibodies, as it can be transferred by serum from protected mice...
  51. ncbi CTLA-4-mediated inhibition in regulation of T cell responses: mechanisms and manipulation in tumor immunotherapy
    C A Chambers
    University of Massachusetts Medical School, Worcester, Massachusetts 01655, USA
    Annu Rev Immunol 19:565-94. 2001
    ..This review primarily focuses on the cellular and molecular mechanisms of regulation by CTLA-4 and its manipulation as a strategy for tumor immunotherapy...
  52. ncbi Augmentation versus inhibition: effects of conjunctional OX-40 receptor monoclonal antibody and IL-2 treatment on adoptive immunotherapy of advanced tumor
    J Kjaergaard
    Center for Surgery Research and Lerner Institute, Cleveland Clinic Foundation, Cleveland, OH 44195, USA
    J Immunol 167:6669-77. 2001
    ..Our study suggests OX-40R mAb to be a reagent of choice to augment T cell adoptive immunotherapy in clinical trials...
  53. ncbi Imaging of mouse experimental melanoma in vivo and ex vivo by combination of confocal and nonlinear microscopy
    Oleksandr Chernyavskiy
    Department of Biomathematics, Institute of Physiology, Academy of Sciences of the Czech Republic, v v i, Videnska 1083, 14220 Prague 4, Czech Republic
    Microsc Res Tech 72:411-23. 2009
    ..possibilities of the combination of the one- and two-photon excitation microscopy for examination of the experimental melanoma tissue in vivo, in mice under general anesthesia, and ex vivo on freshly harvested specimens...
  54. ncbi Multiple pathways to tumor immunity and concomitant autoimmunity
    Mary Jo Turk
    1Weill Graduate School of Medical Sciences of Cornell University, New York, USA
    Immunol Rev 188:122-35. 2002
    ..Autoimmunity uses similar mechanisms as tumor immunity, but tumor immunity and autoimmunity can uncouple. These studies open up strategies for active immunization against cancer...
  55. ncbi Pulsing of dendritic cells with cell lysates from either B16 melanoma or MCA-106 fibrosarcoma yields equally effective vaccines against B16 tumors in mice
    P Dematos
    Department of Surgery, Duke University Medical Center, Durham, North Carolina 27710, USA
    J Surg Oncol 68:79-91. 1998
    ....
  56. ncbi Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance
    T Boehm
    Department of Surgery, Harvard Medical School, Boston, Massachusetts 02115, USA
    Nature 390:404-7. 1997
    ..An unexpected finding is that repeated cycles of antiangiogenic therapy are followed by prolonged tumour dormancy without further therapy...
  57. ncbi In melanoma, RAS mutations are accompanied by switching signaling from BRAF to CRAF and disrupted cyclic AMP signaling
    Nicolas Dumaz
    Signal Transduction Team, The Institute for Cancer Research, Cancer Research UK Centre of Cell and Molecular Biology, London, United Kingdom
    Cancer Res 66:9483-91. 2006
    ..These data have important implications for the development of therapeutic strategies to treat this life-threatening disease...
  58. pmc Self-antigen-specific CD8+ T cell precursor frequency determines the quality of the antitumor immune response
    Gabrielle A Rizzuto
    Departments of Medicine and Immunology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    J Exp Med 206:849-66. 2009
    ..Further, precursor frequency as an isolated variable can be exploited to augment efficacy of clinical vaccine strategies designed to activate any antigen-specific CD8(+) T cells...
  59. pmc T cell homeostatic proliferation elicits effective antitumor autoimmunity
    Wolfgang Dummer
    Department of Immunology, The Scripps Research Institute, La Jolla, California 92037, USA
    J Clin Invest 110:185-92. 2002
    ..The results indicate that concomitant induction of the physiologic processes of homeostatic T cell proliferation and tumor antigen presentation in lymph nodes triggers a beneficial antitumor autoimmune response...
  60. ncbi Stimulation of tumor growth and angiogenesis by low concentrations of RGD-mimetic integrin inhibitors
    Andrew R Reynolds
    Tumour Angiogenesis Group, The Breakthrough Breast Cancer Research Centre, The Institute of Cancer Research, London, UK
    Nat Med 15:392-400. 2009
    ..The proangiogenic effects of low concentrations of RGD-mimetic integrin inhibitors could compromise their efficacy as anticancer agents and have major implications for the use of RGD-mimetic compounds in humans...
  61. ncbi In vivo antitumor activity of interleukin 21 mediated by natural killer cells
    Gang Wang
    Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA
    Cancer Res 63:9016-22. 2003
    ..Our study suggests that IL-21 has significant antitumor activity and may have therapeutic potentials as an antitumor agent in the clinic...
  62. ncbi Induction of lymphoidlike stroma and immune escape by tumors that express the chemokine CCL21
    Jacqueline D Shields
    Institute of Bioengineering, Ecole Polytechnique Federale de Lausanne, 1015 Lausanne, Switzerland
    Science 328:749-52. 2010
    ..We suggest that by altering the tumor microenvironment, CCL21-secreting tumors shift the host immune response from immunogenic to tolerogenic, which facilitates tumor progression...
  63. ncbi Radiotherapy potentiates the therapeutic efficacy of intratumoral dendritic cell administration
    Seagal Teitz-Tennenbaum
    Departments of Surgery, University of Michigan Medical Center, Ann Arbor, Michigan, USA
    Cancer Res 63:8466-75. 2003
    ..i.t. DC administration combined with RT induces a potent local and systemic antitumor response in tumor-bearing mice. This novel regimen may be beneficial in the treatment of human cancers...
  64. ncbi Angiogenesis, lymphangiogenesis, and melanoma metastasis
    Michael Streit
    Berlex Biosciences, Richmond, CA 94804, USA
    Oncogene 22:3172-9. 2003
    ..These observations have important implications for prognosis and treatment of human melanomas...
  65. pmc Overexpression of heme oxygenase-1 in murine melanoma: increased proliferation and viability of tumor cells, decreased survival of mice
    Halina Was
    Department of Medical Biotechnology, Faculty of Biotechnology, Jagiellonian University, Gronostajowa 7, 30 387 Krakow, Poland
    Am J Pathol 169:2181-98. 2006
    ....
  66. ncbi Earlier onset of syngeneic tumors in the presence of mesenchymal stem cells
    Farida Djouad
    INSERM U475, Montpellier, France
    Transplantation 82:1060-6. 2006
    ..However, because of their immunosuppressive capacities, we investigated the effect of MSC on the development of syngeneic tumors...
  67. ncbi Bone morphogenic proteins are overexpressed in malignant melanoma and promote cell invasion and migration
    Tanja Rothhammer
    University of Regensburg Medical School, Regensburg, Germany
    Cancer Res 65:448-56. 2005
    ....
  68. ncbi Platelet-activating factor induces up-regulation of antiapoptotic factors in a melanoma cell line through nuclear factor-kappaB activation
    Kook Heon Seo
    Department of Biological Sciences, The Institute of Basic Sciences, Chonnam National University, Kwangju, Republic of Korea
    Cancer Res 66:4681-6. 2006
    ..These data indicate that PAF induces up-regulation of antiapoptotic factors in a NF-kappaB-dependent manner in a melanoma cell line, therefore suggesting that PAF may diminish the cytotoxic effect of chemotherapeutic agents...
  69. pmc Acquisition of full effector function in vitro paradoxically impairs the in vivo antitumor efficacy of adoptively transferred CD8+ T cells
    Luca Gattinoni
    Center for Cancer Research, National Cancer Institute, NIH, Bethesda, Maryland 20892 1502, USA
    J Clin Invest 115:1616-26. 2005
    ..These findings suggest that the current methodology for selecting T cells for transfer is inadequate and provide new criteria for the generation and the screening of optimal lymphocyte populations for adoptive immunotherapy...
  70. ncbi A comparison and critical analysis of preclinical anticancer vaccination strategies
    J N Kochenderfer
    Experimental Transplantation and Immunology Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, USA
    Exp Biol Med (Maywood) 232:1130-41. 2007
    ..Identification of vaccine characteristics that are associated with antitumor efficacy may aid in the development of more effective anticancer vaccination strategies...
  71. pmc Statins stimulate in vitro membrane FasL expression and lymphocyte apoptosis through RhoA/ROCK pathway in murine melanoma cells
    Guillaume Sarrabayrouse
    INSERM, U563, Toulouse, F 31300 France
    Neoplasia 9:1078-90. 2007
    ..Our results suggest that RhoA/ROCK inhibition could be an interesting target to control FasL expression and lymphocyte apoptosis induced by melanoma cells...
  72. ncbi Combined triggering of dendritic cell receptors results in synergistic activation and potent cytotoxic immunity
    James W Wells
    Medical Research Council and Asthma UK Centre in Allergic Mechanisms of Asthma, King s College London, Guy s Hospital, United Kingdom
    J Immunol 181:3422-31. 2008
    ..This flexible strategy is more effective than existing adjuvants and provides a technological platform for rapid vaccine development...
  73. pmc Decreased tumor surveillance in perforin-deficient mice
    M E van den Broek
    Institute of Experimental Immunology, University of Zurich, Switzerland
    J Exp Med 184:1781-90. 1996
    ....
  74. ncbi Differentially oriented populations of actin filaments generated in lamellipodia collaborate in pushing and pausing at the cell front
    Stefan A Koestler
    Institute of Molecular Biotechnology, Austrian Academy of Sciences, Dr Bohr Gasse 3, 1030, Vienna, Austria
    Nat Cell Biol 10:306-13. 2008
    ....
  75. ncbi The contribution of NKT cells, NK cells, and other gamma-chain-dependent non-T non-B cells to IL-12-mediated rejection of tumors
    Se Ho Park
    Department of Molecular Biology, Princeton University, Princeton, NJ 08540, USA
    J Immunol 170:1197-201. 2003
    ..These findings challenge the view that NKT cells are systematically required for IL-12-mediated rejection of tumors, and instead reveal that a variety of effector pathways can be recruited depending on the tumor microenvironment...
  76. ncbi An intracellular form of cathepsin B contributes to invasiveness in cancer
    A M Szpaderska
    Division of Molecular and Cellular Biochemistry, Department of Cell Biology, Neurobiology and Anatomy, Loyola University Medical Center, 2160 South First Avenue, Maywood, Illinois 60153, USA
    Cancer Res 61:3493-500. 2001
    ..They also indicate that caution should be exercised in assuming that CA-074 is unable to enter cells when it is used to inhibit biological processes of long duration...
  77. pmc Changes in expression of putative antigens encoded by pigment genes in mouse melanomas at different stages of malignant progression
    S J Orlow
    Ronald O Perelman Department of Dermatology, New York University School of Medicine, New York 10016, USA
    Proc Natl Acad Sci U S A 92:10152-6. 1995
    ....
  78. pmc NO mediates mural cell recruitment and vessel morphogenesis in murine melanomas and tissue-engineered blood vessels
    Satoshi Kashiwagi
    Edwin L Steele Laboratory, Department of Radiation Oncology, and Cardiovascular Research Center, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA
    J Clin Invest 115:1816-27. 2005
    ..These data indicate that endothelial cell-derived NO induces mural cell recruitment as well as subsequent morphogenesis and stabilization of angiogenic vessels...
  79. ncbi Green tea polyphenol epigallocatechin-3-gallate signaling pathway through 67-kDa laminin receptor
    Daisuke Umeda
    Laboratory of Food Chemistry, Division of Applied Biological Chemistry, Department of Bioscience and Biotechnology, Faculty of Agriculture, Kyushu University, Fukuoka 812 8581, Japan
    J Biol Chem 283:3050-8. 2008
    ..Additionally, we found that eEF1A is up-regulated by EGCG through 67LR. Overall, these findings implicate both eEF1A and MYPT1 in EGCG signaling for cancer prevention through 67LR...
  80. ncbi Modulatory effect of killed Propionibacterium acnes and its purified soluble polysaccharide on peritoneal exudate cells from C57Bl/6 mice: major NKT cell recruitment and increased cytotoxicity
    R Z Ananias
    Disciplina de Imunologia, Departamento de Microbiologia, Imunologia e Parasitologia, Universidade Federal de Sao Paulo, Sao Paulo, Brazil
    Scand J Immunol 65:538-48. 2007
    ..Macrophages induced by both P. acnes and PS have their antitumour effect dependent on NO production...
  81. pmc Liposome-encapsulated prednisolone phosphate inhibits growth of established tumors in mice
    Raymond M Schiffelers
    Department of Pharmaceutics, Utrecht Institute for Pharmaceutical Sciences UIPS, Utrecht, The Netherlands
    Neoplasia 7:118-27. 2005
    ..In conclusion, the present study shows potent antitumor effects of liposomal formulations of glucocorticoids in a low dose and low-frequency schedule, offering promise for liposomal glucocorticoids as novel antitumor agents...
  82. ncbi Administration of a liposomal FGF-2 peptide vaccine leads to abrogation of FGF-2-mediated angiogenesis and tumor development
    S M Plum
    EntreMed, Inc, 9640 Medical Center Drive, Rockville, MD 20850, USA
    Vaccine 19:1294-303. 2000
    ..These data suggest that a heparin binding domain peptide of FGF-2, when presented to a host in a liposomal adjuvant formulation, can ultimately lead to inhibition of angiogenesis and tumor growth...
  83. ncbi Engagement of the OX-40 receptor in vivo enhances antitumor immunity
    A D Weinberg
    Earle A Chiles Research Institute, Robert W Franz Cancer Research Center, Providence Portland Medical Center, Portland, OR 97213, USA
    J Immunol 164:2160-9. 2000
    ....
  84. ncbi 7th Jan Waldenström Lecture. The biology of human cancer metastasis
    I J Fidler
    Department of Cell Biology, University of Texas M. D. Anderson Cancer Center, Houston
    Acta Oncol 30:668-75. 1991
    ..These data suggest that systemic physiological signals can be usurped by neoplastic cells. Collectively, the factors that regulate metastasis are the intrinsic properties of metastatic cells and host factors involved in homeostasis...
  85. pmc High-avidity autoreactive CD4+ T cells induce host CTL, overcome T(regs) and mediate tumor destruction
    Andrew G Brandmaier
    Department of Surgery, Indiana University School of Medicine, and the Walther Oncology Center, Indianapolis, IN 46202, USA
    J Immunother 32:677-88. 2009
    ..These findings suggest that high-avidity CD4+ T cells can overcome endogenous conditions and mediate their antitumor effects exclusively through the elicitation of CD8+ T cell immunity...
  86. ncbi In vivo manipulation of dendritic cells overcomes tolerance to unmodified tumor-associated self antigens and induces potent antitumor immunity
    Fumiyoshi Okano
    Department of Pathology, Stanford University School of Medicine, Palo Alto, CA 94304, USA
    J Immunol 174:2645-52. 2005
    ..These findings demonstrate that unmodified tumor-associated self Ags can be targeted to DCs in vivo to induce potent systemic antitumor immunity...
  87. ncbi Relevance of the tumor antigen in the validation of three vaccination strategies for melanoma
    M Bellone
    Laboratory of Tumor Immunology, Cancer Immunotherapy and Gene Therapy Program, H San Raffaele Scientific Institute, Milan, Italy
    J Immunol 165:2651-6. 2000
    ..Our results strongly emphasize the relevance of the tumor Ag in the definition of immunotherapeutic strategies for cancer, and support the use of peptide-pulsed DC as cancer vaccine in humans...
  88. pmc The tumorigenic and angiogenic effects of MGSA/GRO proteins in melanoma
    H Haghnegahdar
    Department of Cell Biology, Vanderbilt University School of Medicine, Nashville, Tennessee 37232, USA
    J Leukoc Biol 67:53-62. 2000
    ..These data suggest that continuous expression of MGSA/GRO proteins may facilitate tumor growth by stimulating the growth of microvessels into the tumor (paracrine) and by affecting melanocyte growth (autocrine)...
  89. ncbi Induction of antitumor immunity with dendritic cells transduced with adenovirus vector-encoding endogenous tumor-associated antigens
    J M Kaplan
    Genzyme Corporation, Genzyme Molecular Oncology, Framingham, MA 01701, USA
    J Immunol 163:699-707. 1999
    ..Taken together, these results support the concept of cancer immunotherapy using DCs transduced with Ad vectors encoding tumor-associated Ags...
  90. ncbi A modified tyrosinase-related protein 2 epitope generates high-affinity tumor-specific T cells but does not mediate therapeutic efficacy in an intradermal tumor model
    Jennifer A McWilliams
    Department of Pharmacology, 3M Pharmaceuticals, St Paul, MN 55144, USA
    J Immunol 177:155-61. 2006
    ..However, consistent with most clinical data, simple generation of higher affinity T cells is insufficient to mediate tumor immunity...
  91. ncbi Expression of heat-stable antigen on tumor cells provides co-stimulation for tumor-specific T cell proliferation and cytotoxicity in mice
    Y C Wang
    Department of Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, GA 30322, USA
    Eur J Immunol 25:1163-7. 1995
    ..In summary, our study demonstrated that HSA can provide a co-stimulatory signal for the T cell immune response against tumor cells in a murine model...
  92. ncbi CD4+CD25+ T regulatory cells suppress NK cell-mediated immunotherapy of cancer
    Mark J Smyth
    Cancer Immunology Program, Trescowthick Laboratories, Peter MacCallum Cancer Centre, East Melbourne, Australia
    J Immunol 176:1582-7. 2006
    ..Our data illustrate at least one mechanism by which Treg can suppress NK cell antitumor activity and highlight the effectiveness of combining Treg inhibition with subsequent NK cell activation to promote strong innate antitumor immunity...
  93. ncbi Vaccination with viable human umbilical vein endothelial cells prevents metastatic tumors by attack on tumor vasculature with both cellular and humoral immunity
    Xin Yuan Chen
    Institute of Molecular Medicine and State Key Laboratory of Pharmaceutical Biotechnology, Nanjing University, 22 Hankou Road, Nanjing 210093, China
    Clin Cancer Res 12:5834-40. 2006
    ..Because tumor endothelium is rarely targeted by immunity but is critically important for tumor growth, the immunity against tumor endothelium is to be developed as a novel antitumor strategy...
  94. ncbi Incomplete differentiation of antigen-specific CD8 T cells in tumor-draining lymph nodes
    Kristian M Hargadon
    Department of Microbiology and Carter Immunology Center, University of Virginia Health System, Charlottesville, VA 22908, USA
    J Immunol 177:6081-90. 2006
    ..Thus, activated T cells lacking effector function develop through incomplete differentiation in the lymph nodes of late-stage tumor-bearing mice, rather than through suppression of previously differentiated cells...
  95. ncbi Effect of blocking TNF on IL-6 levels and metastasis in a B16-BL6 melanoma/mouse model
    S Cubillos
    Laboratorio de Fisiopatologia, Instituto Venezolano de Investigaciones Cientificas (IVIC, Caracas, Venezuela
    Anticancer Res 17:2207-11. 1997
    ..The results suggest that the reduction in the number of metastases may be related to the effect of blocking TNF activity...
  96. pmc Subcellular localization of myosin-V in the B16 melanoma cells, a wild-type cell line for the dilute gene
    A A Nascimento
    Department of Morphology, Faculdade de Medicina de Ribeirao Preto Universidade de Sao Paulo, Brazil
    Mol Biol Cell 8:1971-88. 1997
    ....
  97. ncbi Geranylgeranyl transferase inhibition stimulates anti-melanoma immune response through MHC Class I and costimulatory molecule expression
    A F Tilkin-Mariame
    INSERM U563 CPTP, Département Innovation thérapeutique et Oncologie Moléculaire, Toulouse, France
    FASEB J 19:1513-5. 2005
    ..These observations indicate that protein geranylgeranylation as well as Rho protein are critical for costimulatory and IFN-gamma-dependent MHC class I molecule expression in melanoma...
  98. pmc Antitumor activity of liposomal prednisolone phosphate depends on the presence of functional tumor-associated macrophages in tumor tissue
    Manuela Banciu
    Department of Pharmaceutics, Utrecht Institute for Pharmaceutical Sciences UIPS, Utrecht University, Utrecht, The Netherlands
    Neoplasia 10:108-17. 2008
    ..One of the major inhibitory actions of LCL-PLP on tumor growth is the reduction of the TAM-mediated production of pro-angiogenic factors, whereas production of anti-angiogenic factors by these cells is hardly affected...
  99. ncbi Characterization of the major histocompatibility complex class I deficiencies in B16 melanoma cells
    B Seliger
    Johannes Gutenberg Universitat, III Medizinische Klinik, Mainz, Germany
    Cancer Res 61:1095-9. 2001
    ....
  100. pmc B16 as a mouse model for human melanoma
    W W Overwijk
    National Cancer Institute, NIH, Bethesda, Maryland, USA
    Curr Protoc Immunol . 2001
    ..Additional sections, including growing B16 melanoma, enumerating pulmonary metastases, and use of recombinant viruses for vaccination, are discussed together with safety concerns...
  101. ncbi Inhibition of alpha(4) integrin mediated adhesion was involved in the reduction of B16-F10 melanoma cells lung colonization in C57BL/6 mice treated with gambogic acid
    Jie Zhao
    Jiangsu Key Laboratory of Carcinogenesis and Intervention China Pharmaceutical University, Nanjing, PR China
    Eur J Pharmacol 589:127-31. 2008
    ..Thus we concluded for the first time that gambogic acid could inhibit the adhesion and migration of B16-F10 cells in vitro and in vivo, in which down-regulation of alpha(4) integrin expression was involved...

Research Grants65

  1. Inhibition of Melanoma metastasis by Eristostatin
    Mary Ann McLane; Fiscal Year: 2001
    ..The specific goal proposed here is to investigate hoe eristostatin inhibits experimental melanoma metastasis by pursuing three specific aims: i) Create a panel of eristostatin mutations designed to alter ..
  2. MELANOTIC EXPRESSION IN CARCINOGEN-INDUCED MELANOMAS
    J Whittaker; Fiscal Year: 1980
    ..between melanotic expression, growth activities, and various aspects of tumorigenesis and malignancy in experimental melanoma tumors of the Syrian hamster...
  3. TUMOR SUPPRESSOR GENES IN HERITABLE MELANOMA MODELS
    Rodney Nairn; Fiscal Year: 2007
    ..of melanoma formation in Xiphophorus, thereby providing greater scope for exploitation of this unique experimental melanoma model...
  4. BIOEFFECTS OF GAS BODY ACTIVATION IN MEDICAL ULTRASOUND
    Douglas Miller; Fiscal Year: 2009
    ..This project will examine bioeffects in cells and tissues and show how to safely use ultrasound contrast agents in diagnostic imaging. ..
  5. ULTRASOUND ENHANCEMENT OF CANCER GENE THERAPY
    Douglas Miller; Fiscal Year: 2002
    ..This research will provide a bridge from the basic research breakthrough to specific therapeutic applications and urgently needed clinical research programs utilizing this novel technology. ..
  6. ULTRASOUND ENHANCEMENT OF CANCER GENE THERAPY
    Douglas Miller; Fiscal Year: 2003
    ..This research will provide a bridge from the basic research breakthrough to specific therapeutic applications and urgently needed clinical research programs utilizing this novel technology. ..
  7. BIOEFFECTS OF GAS BODY ACTIVATION IN MEDICAL ULTRASOUND
    Douglas Miller; Fiscal Year: 2001
    ..abstract_text> ..
  8. Immunochaperone-based gene therapy targeting prostate cancer
    Xiang yang Wang; Fiscal Year: 2007
    ..The proposed research could lead to the design of a clinical trial for patients with prostate cancer in the very near future. [unreadable] [unreadable] [unreadable]..
  9. Migration of Mature and Immature Dendritic Cells
    HENDRIK VAN DEVENTER; Fiscal Year: 2006
    ..All have extensive experience in developing the careers o f young scientists. This work has the support of the Lineberger Comprehensive Cancer Center which has made accessible its core facilities. ..
  10. Vitiligo in Tyrosinase-specific TCR Transgenic Mice
    VICTOR ENGELHARD; Fiscal Year: 2005
    ..abstract_text> ..
  11. IDENTIFICATION OF HUMAN MINOR H ANTIGEN PEPTIDES & GENES
    VICTOR ENGELHARD; Fiscal Year: 2003
    ..abstract_text> ..
  12. Antigenic determinants on HLA-B7 and-A2
    VICTOR ENGELHARD; Fiscal Year: 2006
    ..Collectively, these studies will continue to use mass spectrometry to offer insight into the display of peptides by MHC molecules of cancer cells, and the relevance of this display to control of tumors by the immune system. ..
  13. CNS Anti-tumor immunity induced by dendritic cell vaccination and TLR agonists
    Robert M Prins; Fiscal Year: 2010
    ..Thus, this is a mechanistic and translational project that is directly related to our long-term objectives stated above and to the mission of promoting public health. ..
  14. Subharmonic Microbubble Signals for Pressure Estimation
    Flemming Forsberg; Fiscal Year: 2008
    ..This will allow potentially life-threatening diseases, such as increased pressure in the liver, to be diagnosed early. [unreadable] [unreadable] [unreadable]..
  15. A tyrosinase-targeted drug design for the treatment of melanoma
    Majid Moridani; Fiscal Year: 2007
    ..In this work we will be developing novel phenol based drugs for treatment of melanoma. [unreadable] [unreadable] [unreadable]..
  16. Contrast-Enhanced Ultrasound Detection of Angiogenesis
    Flemming Forsberg; Fiscal Year: 2004
    ..If successful, this project will permit non-invasive ultrasound evaluations of anti-angiogenic tumor therapies in animals as well as humans. ..
  17. AFP-Based Immunotherapy for Hepatocellular Carcinoma
    Antoni Ribas; Fiscal Year: 2006
    ..In summary, I propose a clinically-oriented research program that translates this original work into novel, evidence-based immnunotherapy trials for hepatocellular carcinoma. ..
  18. Mast Cells and IBD Pathogenesis
    LAURA HALE; Fiscal Year: 2007
    ..unreadable] [unreadable] [unreadable]..
  19. Neoadjuvant Cytokine Immunotherapy by PLA Microspheres
    Michael Sabel; Fiscal Year: 2007
    ..I will pursue this area of investigation as a full-time faculty member, with full commitment from the Department of General Surgery and the Division of Surgical Oncology at the University of Michigan Medical Center. ..
  20. Targeting Vasculogenesis and Interstitial Hypertension in Neurofibromatosis Type1
    Ugur Ozerdem; Fiscal Year: 2007
    ..unreadable] [unreadable] [unreadable]..
  21. US Detection of Sentinel Lymph Nodes in Melanoma
    Barry Goldberg; Fiscal Year: 2006
    ..The results will be compared to histopathological assessment of lymph node status [including ribonucleic acid (RNA) extraction and analysis] as the gold standard. ..
  22. Electrically Mediated Delivery of Immunostimulatory DNA to Experimental Melanomas
    Loree Heller; Fiscal Year: 2006
    ..unreadable] [unreadable]..
  23. Control of Dendritic Cell Generation and Function by Tumor
    Michael Shurin; Fiscal Year: 2008
    ..Additionally, understanding the mechanisms responsible for DC dysfunction in cancer will serve as a basis for developing novel therapeutic approaches for patients with cancer. ..
  24. Neural Progenitor Cells as Cancer Therapy Vectors
    Karen Aboody; Fiscal Year: 2009
    ..The described approach might then be adapted to the treatment of other solid tumors by careful choice of appropriate therapeutic transgenes. ..
  25. Control of Eye Melanoma Metastsis
    Hans E Grossniklaus; Fiscal Year: 2010
    ..The third aim determines the mechanism of combined angiostatin/IFN control of the micrometastases using methods in the first two aims. ..
  26. Targeting Metastatic Breast Cancer with Human Antibodies
    Brunhilde Felding Habermann; Fiscal Year: 2009
    ..Novel immunoconjugates containing small, highly toxic compounds will be tested for their effects on metastatic breast cancer. If successful, this work will contribute to an improvement of current anti-cancer treatment. ..
  27. Development of a nanosecond pulsed electric field system to treat skin cancer
    Richard Nuccitelli; Fiscal Year: 2008
    ..It offers a scar-free alternative to surgery that could improve the quality of life for tens of thousands of dermatology patients. [unreadable] [unreadable] [unreadable]..
  28. Interaction of AIDS-associated microbes with radiation
    Ekaterina Dadachova; Fiscal Year: 2009
    ..Such knowledge will contribute to development of a novel therapeutic modality based on radioimmunotherapy for treatment of currently incurable or multidrug-resistant AIDS-associated opportunistic infections. ..
  29. Mitochondrial translocation of p53 and its interaction with manganese superoxide
    Yunfeng Zhao; Fiscal Year: 2008
    ..Overall, these studies will help to understand the apoptotic mechanisms during tumorigenesis, leading to a better design of apoptosis-aimed cancer prevention. [unreadable] [unreadable] [unreadable] [unreadable]..
  30. Targeting GITR for Tumor Immunotherapy
    Adam Cohen; Fiscal Year: 2008
    ..Gaining greater mechanistic understanding of the effects of anti-GITR antibody on tumor immunity will allow for more rational translation of this promising immunotherapeutic approach to the clinic. [unreadable] [unreadable] [unreadable]..
  31. Imaging Nanocomposites Targeting Tumor Microvasculature
    Mohamed Khan; Fiscal Year: 2008
    ..3) intracellular, intratumoral, and whole animal imaging will be accomplished via Transmission Electron Micrography (TEM), an autoradiography and immunohistochemical method, and SPECT imaging respectively. ..
  32. Nanoparticle targeting of cathepsin-L inhibitor and doxorubicin in breast cancer
    Shaker Mousa; Fiscal Year: 2007
    ..unreadable] [unreadable] [unreadable]..
  33. Ligand for Natural Cytotoxicity Receptor NKp44
    PORUNELLOOR MATHEW; Fiscal Year: 2008
    ..This information will be useful in developing immune based treatment for cancer and other diseases. [unreadable] [unreadable] [unreadable] [unreadable]..
  34. Optimizing T cell Immunity to Cancer Vaccines
    Miguel Angel Perales; Fiscal Year: 2006
    ..This environment maximizes the potential for the principal investigator to establish a successful independent research program. [unreadable] [unreadable]..
  35. Carbohydrate-carbohydrate interaction in basic cell biology
    Sen itiroh Hakomori; Fiscal Year: 2006
    ..abstract_text> ..
  36. Aging and the Microvasculature
    May Reed; Fiscal Year: 2006
    ..The results will define the key points of deficient microvascular growth in the aged and also develop the microvessel sprout model into a highly useful tool for studies of vascular growth in general. ..
  37. FLOW CYTOMETRY INSTRUMENT
    ZUHAIR BALLAS; Fiscal Year: 2001
    ..abstract_text> ..
  38. REGULATION OF ORNITHINE DECARBOXYLASE BY PHORBOL ESTERS
    Andrew Butler; Fiscal Year: 2002
    ..Taken together, these studies should provide new insight into the mechanisms by which tumor promoters and oncogenes influence ODC regulation and corrupt patterns of gene expression during carcinogenesis. ..
  39. SPHINGOSINE DEPENDENT KINASE AND CARCINOGENESIS
    Senitiroh Hakomori; Fiscal Year: 2003
    ..In the inhibitory effect is confirmed, its mechanism will be studied in relation to activities of SDKs, MAPK, bcl-2, and other signal transducers. ..
  40. PLASMALOPSYCHOSINE AS NEUROTROPHIC FACTOR
    Senitiroh Hakomori; Fiscal Year: 2003
    ..Results of these studies may provide a basis for development of PLPS and its analogues as therapeutic reagents for neurodegenerative diseases and neuronal injury. ..
  41. Radioimmunotherapy of opportunistic infections
    Ekaterina Dadachova; Fiscal Year: 2003
    ..It will also provide some understanding of the fundamentals of interactions between microorganisms and antibodies radiolabeled with particulate-emitting radioisotopes in vitro and in vivo. ..
  42. PREVENTING ANTI-GAL PRODUCTION AGAINST XENOGRAFTS
    Uri Galili; Fiscal Year: 2003
    ..Success in these studies will help in planning effective treatments for preventing anti-Gal response in primate xenografts recipients. | ..
  43. Rhenium-188 therapy of NIS-expressing breast tumors
    Ekaterina Dadachova; Fiscal Year: 2003
    ..The long-term goal of this research is to contribute to the development of a novel cost-effective radionuclide therapy for treatment of breast cancer and, possibly, for other NIS-expressing cancers such as thyroid cancer. ..
  44. Anti-ABeta Immunity Against Alzheimer's Disease
    Kenneth Ugen; Fiscal Year: 2003
    ..These studies will comprehensively address the potential role of cellular immune responses to Abeta vaccines. ..
  45. MODULATING AUTOIMMUNE DISEASE BY FC RECEPTORS
    Jeffrey Ravetch; Fiscal Year: 2004
    ..These studies will dissect the novel, FcR-dependent pathways involved in autoimmunity and exploit these observations for the development of innovative therapies. ..
  46. STUDY OF FC RECEPTOR GENES: MACROPHAGES AND LYMPHOCYTES
    Jeffrey Ravetch; Fiscal Year: 2007
    ..unreadable]..
  47. Cell type gene delivery and alcoholic liver disease
    Michael Wheeler; Fiscal Year: 2006
    ..In addition, through didactic training, and interactions with his mentor and key faculty, the applicant will acquire new skills that will allow him to become a successful member of the alcohol research community. ..
  48. Integrin Activation in Breast Cancer Metastasis
    Brunhilde Felding Habermann; Fiscal Year: 2006
    ....
  49. Bromelain as a Biologically-Based Therapy for IBD
    LAURA HALE; Fiscal Year: 2005
    ..This research will thus strengthen the biomedical research knowledge base needed to inform the practice of complementary and alternative medicine. ..
  50. ROLE OF THE PTEN PATHWAY IN MELANOMA
    Marcus Bosenberg; Fiscal Year: 2005
    ..He has also completed Ph.D. training in cell biology. The proposed research will be carried out in the laboratory of Dr. Ronald DePinho at the Dana-Farber Cancer Institute, an affiliate of the Harvard Medical School. ..
  51. Non-viral Cutaneous Gene Delivery
    Mohammed Kashani Sabet; Fiscal Year: 2005
    ..We will determine whether efficient expression of the XPC gene in mice will alter the response to UV-mediated DNA damage. ..
  52. Second International Melanoma Research Congress
    Meenhard Herlyn; Fiscal Year: 2004
    ..This second congress will strengthen the field and solidify the ties between the different research and clinical communities. ..
  53. IVIS 200 Imaging System
    Brunhilde Felding Habermann; Fiscal Year: 2005
    ..abstract_text> ..
  54. LONG-CIRCULATING TUMOR-SELECTIVE DNA DELIVERY SYSTEMS
    Mansoor Amiji; Fiscal Year: 2005
    ..The results of this study will provide valuable information on the development of safe and efficacious nonviral vectors for in vivo DNA delivery specifically to solid tumor. ..
  55. Functional analysis of Tgfbm3 locus in vascular development and disease
    Rosemary J Akhurst; Fiscal Year: 2010
    ..assessment of disease risk in ailments known to have a TGFB1 associationc) Will provide targets for prophylactic drug development of such diseases d) May provide predictive markers for response to anti-TGFb drug therapies ..
  56. DNA-based Vaccine for Treatment of Oral Carcinoma
    Edward Cohen; Fiscal Year: 2006
    ..It is expected that development of an effective vaccine to be used alone or in combination with conventional therapy will expand the future therapeutic options available for patients with oral cancer. ..
  57. Anti-angiogenic Tetrathiomolybdate +XRT in NSCLC-Phase 1
    Mohamed Khan; Fiscal Year: 2004
    ..Chest CT and Chest x-ray will be taken to record tumor response, and to compare with 99mTc-MIBI scans. ..
  58. Development of an electrical diagnostic for melanoma
    Richard Nuccitelli; Fiscal Year: 2008
    ..If the handheld BFI is able to reliably detect malignant skin lesions, it will improve the quality of life for tens of thousands of dermatology patients in the United States alone. [unreadable] [unreadable] [unreadable]..
  59. ANTITUMOR IMMUNITY INDUCED BY FUSION CELLS VACCINATION
    Jianlin Gong; Fiscal Year: 2003
    ..3). To assess the effectiveness of fusion cell vaccines in the prevention and treatment of spontaneous breast carcinoma in transgenic mice. ..
  60. EXPERIMENTAL TRANSFORMATION OF HUMAN MELANOCYTES IN VIVO
    Meenhard Herlyn; Fiscal Year: 2008
    ..Our unique model allows a systematic dissection of the biological and molecular events leading to human melanoma formation. ..
  61. Uveal Melanoma Micrometastasis
    Pierre L Triozzi; Fiscal Year: 2010
    ..Micrometastases, microscopic deposits of tumor that have spread via the bloodstream, are present in many patients with uveal melanoma at diagnosis. This project will test new methods of identifying and inhibiting these deposits. ..
  62. TUMOR ASSOCIATED DENDRITIC CELLS
    Michael Shurin; Fiscal Year: 2002
    ....